Hudson Bay Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hudson Bay Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-76,500	Closed	-$1.41M	–	763
2024 Q1	$1.41M	Buy	+76,500	New	+$1.9M	0.01%	505
2021 Q4	–	Sell	-171,000	Closed	-$2.84M	–	1075
2021 Q3	$2.84M	Buy	+171,000	New	+$3.3M	0.04%	549
2020 Q3	–	Sell	-30,000	Closed	-$1.45M	–	536
2020 Q2	$1.45M	Buy	+30,000	New	+$1.44M	0.03%	343
2019 Q4	–	Sell	-70,000	Closed	-$2.52M	–	420
2019 Q3	$2.52M	Buy	+70,000	New	+$2.12M	0.07%	233
2018 Q4	–	Sell	-150,000	Closed	-$3.11M	–	762
2018 Q3	$3.11M	Buy	+150,000	New	+$2.36M	0.04%	388

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Hudson Bay Capital Management's ACAD Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 536% in Q1 2026, buying an estimated $8.97M and bringing the position to 445,506 shares worth $9.92M. The position accounts for 0.03% of the portfolio, ranked #317.

Hudson Bay Capital Management first reported a position in ACAD in Q1 2017 and has held it in 25 quarters since. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Hudson Bay Capital Management held 445,506 shares of Acadia Pharmaceuticals worth $9.92M as of Q1 2026.
Hudson Bay Capital Management bought 375,506 Acadia Pharmaceuticals shares in Q1 2026, an estimated $8.97M.
Acadia Pharmaceuticals made up 0.03% of Hudson Bay Capital Management's portfolio in Q1 2026, its #317 holding.
Hudson Bay Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2017 and has held it in 25 quarters since.
342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.